Bosutinib inhibits migration and invasion via ack1 in kras mutant non-small cell lung cancer

Molecular Cancer

Volumn 13, Issue 1, 2014, Pages

  Tan, Daniel S W ^a   Haaland, Benjamin ^b,c   Gan, Jia M ^d   Tham, Su C ^d,i   Sinha, Indrajit ^e   Tan, Eng H ^a   Lim, Kiat H ^f   Takano, Angela ^f   Krisna, Sai S ^a   Thu, Minn Minn M ^f   Liew, Hoe P ^g   Ullrich, Axel ^h   Lim, Wan Teck ^a,b,i   Chua, Boon T ^d,i  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b DUKE NUS MEDICAL SCHOOL   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d INSTITUTE OF MEDICAL BIOLOGY   (Singapore)

^e Biomedcore Inc   (Canada)

^f SINGAPORE GENERAL HOSPITAL   (Singapore)

^g AGENCY FOR SCIENCE   (Singapore)

^h MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

ⁱ INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

Author keywords

ACK1; Bosutinib; KRAS; Lung cancer; Metastasis

Indexed keywords

ANILINE COMPOUNDS; ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL MOVEMENT; GENE KNOCKDOWN TECHNIQUES; HUMANS; LUNG NEOPLASMS; MUTATION; NEOPLASM INVASIVENESS; NITRILES; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; QUINOLINES; RAS PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; TISSUE ARRAY ANALYSIS; XENOGRAFT MODEL ANTITUMOR ASSAYS; ZEBRAFISH;

EID: 84892711477     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-13-13     Document Type: Article

References (32)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Li T, Kung H-J, Mack PC, Gandara DR. Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J Clin Oncol 2013, 31:1039-1049.
3. Tan DSW, Gerlinger M, Teh BT, Swanton C. Anti-cancer drug resistance: understanding the mechanisms through the use of integrative genomics and functional RNA interference. Eur J Cancer 2010, 46:2166-2177.
4. Manser E, Leung T, Salihuddin H, Tan L, Lim L. A non-receptor tyrosine kinase that inhibits the GTPase activity of p21cdc42. Nature 1993, 363:364-367.
5. Kato-Stankiewicz J, Ueda S, Kataoka T, Kaziro Y, Satoh T. Epidermal growth factor stimulation of the ACK1/Dbl pathway in a Cdc42 and Grb2-dependent manner. Biochem Biophys Res Commun 2001, 284:470-477.
6. Teo M, Tan L, Lim L, Manser E. The tyrosine kinase ACK1 associates with clathrin-coated vesicles through a binding motif shared by arrestin and other adaptors. J Biol Chem 2001, 276:18392-18398.
7. Shen F, Lin Q, Gu Y, Childress C, Yang W. Activated Cdc42-associated kinase 1 is a component of EGF receptor signaling complex and regulates EGF receptor degradation. Mol Biol Cell 2007, 18:732-742.
8. Chan W, Tian R, Lee Y-F, Sit ST, Lim L, Manser E. Down-regulation of active ACK1 is mediated by association with the E3 ubiquitin ligase Nedd4-2. J Biol Chem 2009, 284:8185-8194.
9. Mahajan K, Coppola D, Challa S, Fang B, Chen YA, Zhu W, Lopez AS, Koomen J, Engelman RW, Rivera C, Muraoka-Cook RS, Cheng JQ, Schönbrunn E, Sebti SM, Earp HS, Mahajan NP. Ack1 mediated AKT/PKB tyrosine 176 phosphorylation regulates its activation. PLoS ONE 2010, 5:e9646.
10. van der Horst EH, Degenhardt YY, Strelow A, Slavin A, Chinn L, Orf J, Rong M, Li S, See L-H, Nguyen KQC, Hoey T, Wesche H, Powers S. Metastatic properties and genomic amplification of the tyrosine kinase gene ACK1. Proc Natl Acad Sci U S A 2005, 102:15901-15906.
11. Wang L, Zhu J-S, Song M-Q, Chen G-Q, Chen J-L. Comparison of gene expression profiles between primary tumor and metastatic lesions in gastric cancer patients using laser microdissection and cDNA microarray. World J Gastroenterol 2006, 12:6949-6954.
12. Mahajan NP, Liu Y, Majumder S, Warren MR, Parker CE, Mohler JL, Earp HS, Whang YE. Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation. Proc Natl Acad Sci U S A 2007, 104:8438-8443.
13. Mahajan K, Challa S, Coppola D, Lawrence H, Luo Y, Gevariya H, Zhu W, Chen YA, Lawrence NJ, Mahajan NP. Effect of Ack1 tyrosine kinase inhibitor on ligand-independent androgen receptor activity. Prostate 2010, 70:1274-1285.
14. Mahajan K, Coppola D, Chen YA, Zhu W, Lawrence HR, Lawrence NJ, Mahajan NP. Ack1 tyrosine kinase activation correlates with pancreatic cancer progression. Am J Pathol 2012, 180:1386-1393.
15. Eisenmann KM, McCarthy JB, Simpson MA, Keely PJ, Guan JL, Tachibana K, Lim L, Manser E, Furcht LT, Iida J. Melanoma chondroitin sulphate proteoglycan regulates cell spreading through Cdc42, Ack-1 and p130cas. Nat Cell Biol 1999, 1:507-513.
16. Nur-E-Kamal A, Zhang A, Keenan SM, Wang XI, Seraj J, Satoh T, Meiners S, Welsh WJ. Requirement of activated Cdc42-associated kinase for survival of v-Ras-transformed mammalian cells. Mol Cancer Res 2005, 3:297-305.
17. Chua BT, Lim SJ, Tham SC, Poh WJ, Ullrich A. Somatic mutation in the ACK1 ubiquitin association domain enhances oncogenic signaling through EGFR regulation in renal cancer derived cells. Mol Oncol 2010, 4:323-334.
18. Golas JM, Arndt K, Etienne C, Lucas J, Nardin D, Gibbons J, Frost P, Ye F, Boschelli DH, Boschelli F. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res 2003, 63:375-381.
19. Remsing Rix LL, Rix U, Colinge J, Hantschel O, Bennett KL, Stranzl T, Müller A, Baumgartner C, Valent P, Augustin M, Till JH, Superti-Furga G. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia 2009, 23:477-485.
20. Daud AI, Krishnamurthi SS, Saleh MN, Gitlitz BJ, Borad MJ, Gold PJ, Chiorean EG, Springett GM, Abbas R, Agarwal S, Bardy-Bouxin N, Hsyu P-H, Leip E, Turnbull K, Zacharchuk C, Messersmith WA. Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors. Clin Cancer Res 2012, 18:1092-1100.
21. Modzelewska K, Newman LP, Desai R, Keely PJ. Ack1 mediates Cdc42-dependent cell migration and signaling to p130Cas. J Biol Chem 2006, 281:37527-37535.
22. Buettner R, Mesa T, Vultur A, Lee F, Jove R. Inhibition of Src family kinases with dasatinib blocks migration and invasion of human melanoma cells. Mol Cancer Res 2008, 6:1766-1774.
23. Liu Z, Adams HC, Whitehead IP. The rho-specific guanine nucleotide exchange factor Dbs regulates breast cancer cell migration. J Biol Chem 2009, 284:15771-15780.
24. Pao-Chun L, Chan PM, Chan W, Manser E. Cytoplasmic ACK1 interaction with multiple receptor tyrosine kinases is mediated by Grb2: an analysis of ACK1 effects on Axl signaling. J Biol Chem 2009, 284:34954-34963.
25. Konantz M, Balci TB, Hartwig UF, Dellaire G, André MC, Berman JN, Lengerke C. Zebrafish xenografts as a tool for in vivo studies on human cancer. Ann N Y Acad Sci 2012, 1266:124-137.
26. Roberts PJ, Stinchcombe TE. KRAS Mutation: Should We Test for It, and Does It Matter?. J Clin Oncol 2013, 31:1112-1121.
27. Zhang Y-X, Knyazev PG, Cheburkin YV, Sharma K, Knyazev YP, Orfi L, Szabadkai I, Daub H, Kéri G, Ullrich A. AXL is a potential target for therapeutic intervention in breast cancer progression. Cancer Res 2008, 68:1905-1915.
28. Baker AF, Dragovich T, Ihle NT, Williams R, Fenoglio-Preiser C, Powis G. Stability of phosphoprotein as a biological marker of tumor signaling. Clin Cancer Res 2005, 11:4338-4340.
29. Espina V, Edmiston KH, Heiby M, Pierobon M, Sciro M, Merritt B, Banks S, Deng J, VanMeter AJ, Geho DH, Pastore L, Sennesh J, Petricoin EF, Liotta LA. A portrait of tissue phosphoprotein stability in the clinical tissue procurement process. Mol Cell Proteomics 2008, 7:1998-2018.
30. Peinado H, Quintanilla M, Cano A. Transforming growth factor beta-1 induces snail transcription factor in epithelial cell lines: mechanisms for epithelial mesenchymal transitions. J Biol Chem 2003, 278:21113-21123.
31. Schmidt CR, Gi YJ, Patel TA, Coffey RJ, Beauchamp RD, Pearson AS. E-cadherin is regulated by the transcriptional repressor SLUG during Ras-mediated transformation of intestinal epithelial cells. Surgery 2005, 138:306-312.
32. Rachagani S, Senapati S, Chakraborty S, Ponnusamy MP, Kumar S, Smith LM, Jain M, Batra SK. Activated KrasG12D is associated with invasion and metastasis of pancreatic cancer cells through inhibition of E-cadherin. Br J Cancer 2011, 104:1038-1048.